Total and High Molecular Weight Adiponectin and Hepatocellular Carcinoma with HCV Infection by Sumie, Shuji et al.
Total and High Molecular Weight Adiponectin and
Hepatocellular Carcinoma with HCV Infection
Shuji Sumie
1*, Takumi Kawaguchi
1,2, Ryoko Kuromatsu
1, Akio Takata
1, Masahito Nakano
1, Manabu
Satani
1, Shingo Yamada
1, Takashi Niizeki
1, Takuji Torimura
3, Michio Sata
1,2
1Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan, 2Department of Digestive Disease Information and
Research, Kurume University School of Medicine, Kurume, Japan, 3Liver Cancer Research Division, Research Center for Innovative Cancer Therapy, Kurume University,
Kurume, Japan
Abstract
Background: Adiponectin is shown to be inversely associated with development and progression of various cancers. We
evaluated whether adiponectin level was associated with the prevalence and histological grade of hepatocellular carcinoma
(HCC), and liver fibrosis in patients with hepatitis C virus (HCV) infection.
Methods: A case-control study was conducted on 97 HCC patients (cases) and 97 patients (controls) matched for sex, Child-
Pugh grade and platelet count in patients with HCV infection. The serum total and high molecular weight (HMW)
adiponectin levels were measured by enzyme-linked immunosorbent assays and examined in their association with the
prevalence of HCC. In addition, the relationship between these adiponectin levels and body mass index (BMI), progression
of liver fibrosis, and histological grade of HCC was also evaluated. Liver fibrosis was assessed using the aspartate
aminotransferase to platelet ratio index (APRI).
Results: There were no significant differences in the serum total and HMW adiponectin levels between cases and controls.
Moreover, there were no inverse associations between serum total and HMW adiponectin levels and BMI in both cases and
controls. On the other hand, serum total and HMW adiponectin levels are positively correlated with APRI in both cases
(r=0.491, P,0.001 and r=0.485, P,0.001, respectively) and controls (r=0.482, P,0.001 and r=0.476, P,0.001,
respectively). Interestingly, lower serum total (OR 11.76, 95% CI: 2.97–46.66 [P,0.001]) and HMW (OR 10.24, CI: 2.80–
37.40 [P,0.001] adiponectin levels were independent risk factors of worse histological grade of HCC.
Conclusions: Our results suggested that serum total and HMW adiponectin levels were predictors of liver fibrosis, but not
prevalence of HCC in patients with HCV infection. Moreover, low these adiponectin levels were significantly associated with
worse histological grades.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most common
malignancies in the world. The incidence of HCC has increased in
Eastern Asia and Africa during the past several decades, and has
also increased in the United States [1]. In many countries, this
trend is attributed to hepatitis C virus (HCV) infections, and in
Japan, over 70% of all HCC are related to chronic liver disease
with HCV infection [2]. In order to prevent and treat this
malignancy, it is important to understand the pathogenesis of
HCC in patients with HCV infection.
Obesity is widely recognized as a significant risk factor for the
development of various cancers [3]. It also is suggested that obesity
is associated with the progression of chronic liver disease [4,5] and
with HCC [6]. Especially, nonalcoholic fatty liver disease is
recognized to be a hepatic manifestation of the metabolic
syndrome and obesity and insulin resistance play a major role in
the pathogenesis [7]. Nonalcoholic fatty liver disease represents a
spectrum of conditions that are histologically characterized from
simple steatosis to nonalcoholic steatohepatits, which is associated
with increased risk of advanced liver fibrosis, cirrhosis and
development of HCC [8]. Similarly, in patients with HCV
infection, several studies have shown that obesity was associated
with disease progression [4,5] and with HCC development [9,10].
However, it is unclear how obesity is linked to development of
HCC in patients with HCV infection.
Adiponectin is a peptide hormone secreted by adipocyte and
hepatocyte [11]. Adiponectin exists primarily in three forms: low
molecular weight trimers, medium molecular weight hexamers,
and high molecular weight (HMW) multimers [12]. Among three
forms, HMW adiponectin is thought to have more biological
activity than other forms of adiponectin [12,13]. Adiponectin has
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and is inversely associated with body mass index (BMI); therefore
it is also linked to the various metabolic abnormalities associated
with obesity [14]. Recently, hypoadiponectinemia has been shown
to be an important risk factor for the development of various
cancers associated with obesity such as breast cancer [15],
endometrial cancer [16], colorectal cancer [17], and gastric
cancer [18]. However, it is still unknown whether adiponectin
contribute to the development of HCC in patients with HCV
infection. Moreover, adiponectin has been shown to be associated
with progression of liver fibrosis in patients with chronic liver
disease [19,20,21]. However, in patients with HCV infection, the
association between adiponectin and liver fibrosis is uncertain.
Histological grade is known to be one of the most important risk
factor for patients with HCC. Several studies have shown that
histological grade affected recurrence and survival after curative
resection and liver transplantation for HCC [22,23]. Although it is
known that worse histological grade is associated with high cell
proliferation and angiogenesis of HCC, these molecular mecha-
nisms is not unclear. Several clinical studies have demonstrated
that serum adiponectin levels were negatively associated with
increasing of histological grades of several cancers [15,24,25].
Therefore, in case-control study, we investigated the association
of serum total and HMW adiponectin levels with prevalence of
HCC in chronic liver disease with HCV infections. In addition,
the associations between these adiponectin levels and BMI,
progression of liver fibrosis, and histological grades of HCC were
also examined.
Materials and Methods
Ethics Statement
The study protocol was approved by The Ethical Committee of
Kurume University, and written informed consent for participa-
tion in the study was obtained from each subject and conformed to
the guidelines of the 1995 Declaration of Helsinki.
Patients
Between January 1997 and December 2007, 97 Japanese cases
with chronic HCV infection at the Kurume University School of
Medicine were diagnosed with HCC and enrolled in this study. All
cases had no medical history of previous or present neoplastic
disease at any other site. The case patients were histologically
confirmed with HCC by needle biopsy, and with a single tumor
#5 cm or three or fewer tumors each #3 cm seen on
ultrasonography and computed tomography. Histological classifi-
cation was based on Liver Cancer Study Group of Japan [26].
According to Edmondson-Steiner classification [27], well differ-
entiated corresponds to grade I and a part of grade II, and
moderately differentiated corresponds to grade II and grade III
with a clear trabecular pattern, and poorly differentiated
corresponds to grade III with an indistinct trabecular pattern
and part of grade IV. Tumor sizes were determined based on the
largest dimension of the tumor. Between January 2005 and
December 2007, 97 patients with chronic HCV infection, who
matched for sex, Child-Pugh grade and platelet count (620610
9/
L), were randomly selected as controls at the same hospital. The
control patients had no medical history of previous or present
neoplastic disease, including HCC. In all cases and controls,
hepatic functional reserve was determined using the Child-Pugh
scoring system. Diabetes was defined as a fasting blood glucose
$126 mg/dl, and/or a random blood glucose $200 mg/dl. BMI
was calculated as body weight in kg divided by the square of the
height in meters (kg/m
2).
Assessment of liver fibrosis
Liver fibrosis was assessed using the aspartate aminotransferase
(AST) to platelet ratio index (APRI) in this study. APRI has been
recognized as a noninvasive test to characterize the degree of liver
fibrosis in chronic liver disease with HCV infection [28]. APRI
was calculated for all study subjects as follows: AST/upper limit of
normal (45 IU/L)6100/platelet count (10
9/L).
Markers of hepatic virus
HCV infection was evaluated using anti-HCV antibody (HCV-
Ab). The diagnosis of HBV infection was also based on detection
of hepatitis B surface antigen (HBsAg). The presence of HCV-Ab
and HBsAg was determined using standard clinical methods
(Department of Clinical Laboratory, Kurume University Hospi-
tal). All cases and controls were positive for HCV-Ab and negative
for HBsAg in this study.
Measurement of serum adiponectin
Fasting morning blood samples were obtained from all subjects
and stored at 220uC for later analysis. Blood samples were
collected by all cases before HCC therapy was initiated. Serum
total and HMW adiponectin levels were measured by enzyme-
linked immunosorbent assays using the Human Adiponectin Latex
Kit (Eiken Chemical Co., Ltd., Tokyo, Japan) and High Molecular
Weight Adiponectin Assay Kit (Fujirebio Inc., Tokyo, Japan),
respectively.
Statistical Analysis
Continuous variables were expressed as mean 6 standard
deviation. Comparisons between the 2 groups were performed
using the Mann-Whitney U test for continuous variables, and the
chi-square test for discrete variables. Pearson correlation test was
used to evaluate the association between plasma total and HMW
adiponectin levels and BMI and APRI in each cases and controls.
Comparison analysis between histological grades was performed
by the one-way ANOVA with Bonferroni corrections for post hoc
comparisons. The relationships between total and HMW adipo-
nectin and HCC histological grades of were determined using
multiple logistic regression models. Data were reported as odds
ratios (ORs) and 95% confidence intervals (95% CIs). All P values
were 2-tailed, and P,0.05 was considered to be statistically
significant. Statistical analysis was performed using SPSS software
(SPSS Inc., Chicago, IL).
Results
Serum adiponectin levels and prevalence of HCC
The baseline clinical characteristics of the 97 cases and 97
controls were shown in Table 1. No significant differences were
found between cases and controls according to AST level, alanine
transaminase (ALT) level, APRI, diabetes mellitus, or BMI. The
mean age of the cases was significantly higher than the mean age
of the controls. The associations between serum total and HMW
adiponectin levels and prevalence of HCC were shown in Figure 1.
There were no significant differences between the mean total
adiponectin levels of the cases and controls (15.5610.4 mg/ml and
16.6612.8 mg/ml, respectively, P=0.670) (Figure 1A), or the
mean HMW adiponectin levels (10.167.4 mg/ml and
10.869.0 mg/ml, respectively, P=0.752) (Figure 1B).
Association between serum adiponectin levels and BMI
We examined the associations between serum total and HMW
adiponectin levels and BMI in cases and controls. In controls,
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adiponectin levels and BMI (r=20.142, P=0.166 for total
adiponectin [Figure 2A] and r=20.144, P=0.160 for HMW
adiponectin [Figure 2B]). Similarly, in cases, there were also no
inverse associations between serum total or HMW adiponectin
levels and BMI (r=20.129, P=0.208 for total adiponectin
[Figure 2C] and r=20.131, P=0.201 for HMW adiponectin
[Figure 2D]).
Association between serum adiponectin levels and APRI
We also evaluated the associations between serum total and
HMW adiponectin levels and APRI in cases and controls. In
controls, serum levels of total and HMW adiponectin were
positively associated with APRI (r=0.482, P,0.001 for total
adiponectin [Figure 3A] and r=0.476, P,0.001 for HMW
adiponectin [Figure 3B]). Similarly, in cases, serum levels of total
and HMW adiponectin were positively associated with APRI
(r=0.491, P,0.001 for total adiponectin [Figure 3C] and
r=0.485, P,0.001 for HMW adiponectin [Figure 3D]).
Comparison of serum adiponectin levels according to
HCC histological grades
The baseline clinical characteristics of 97 HCC cases were also
separately evaluated according to the histological grades (Table 2).
No significant differences were found between HCC histological
grades and age, gender, AST level, ALT level, platelet count,
APRI, Child-Pugh grade, diabetes mellitus, BMI, alpha-fetopro-
tein (AFP) level, des-gamma-carboxy prothrombin (DCP) level,
and number of tumor. Patients with moderately and poorly
differentiated HCC had significantly larger tumor sizes than
patients with well-differentiated HCC. The associations between
serum total and HMW adiponectin levels and HCC histological
grades were shown in Figure 4. The mean total adiponectin levels
in patients with moderately (13.466.9 mg/ml, P=0.001) and
Table 1. Baseline clinical characteristics in case and control.
Case Control P value
Number 97 97
Age (years) 67.468.3 61.2611.4 ,0.001
Gender (Female/Male) 30/67 30/67 Matched variable
AST (U/L) 61.8628.3 60.0628.5 0.632
ALT (U/L) 58.4633.4 60.0631.8 0.513
Platelet (610
9/L) 115.0651.4 115.5652.5 Matched variable
APRI 1.561.0 1.561.1 0.863
Child-Pugh grade (A/B+C) 82/15 82/15 Matched variable
Diabetes mellitus (Absent/Present) 64/33 71/26 0.275
BMI (kg/m
2) 22.563.2 23.163.3 0.228
Total adiponectin (mg/ml) 15.5610.4 16.6612.8 0.670
HMW adiponectin (mg/ml) 10.167.4 10.869.0 0.752
Continuous variables presented as mean 6 standard deviation.
Abbreviation: AST=aspartate aminotransferase; ALT=alanine aminotransferase;
APRI=aspartate aminotransferase-to-platelet ratio index; BMI=body mass index;
HMW=high molecular weigh.
doi:10.1371/journal.pone.0026840.t001
Figure 1. Comparison of adiponectin levels between 97 controls and 97 cases. A. Comparison of total adiponectin levels between patients
with cases and controls (P=0.670). B. Comparison of HMW adiponectin levels between patients with cases and controls (P=0.752).
doi:10.1371/journal.pone.0026840.g001
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significantly lower compared to those in patients with well-
differentiated HCC (22.0613.6 mg/ml). The mean HMW adipo-
nectin levels in patients with moderately (8.664.7 mg/ml, P,0.001)
and poorly (6.965.0 mg/ml, P,0.001) differentiated HCC were
significantly lower compared to those in patients with well-
differentiated HCC (14.969.5 mg/ml). In addition, multiple logistic
regressionanalyseswereperformedto determinewhethertheserum
total and HMW adiponectin levels were independently associated
with HCC histological grades (Table 3). In the analysis adjusted for
other variables, lower serum total adiponectin levels (12–24 mg/ml;
OR:9.33,95% CI:2.27–38.43[P=0.002], ,12 mg/ml; OR11.76,
95% CI: 2.97–46.66 [P,0.001]) and serum HMW adiponectin
levels (7–14 mg/ml; OR: 5.67, 95% CI: 1.66–19.33 [P=0.006],
,7 mg/ml; OR 10.24, CI: 2.80–37.40 [P,0.001]) were indepen-
dent risk factors for worse HCC histological grades.
Discussion
Obesity is known to be associated with various cancers and
hypoadiponectinemia has been also shown to be a risk factor for
these obesity-associated cancers [15,16,17,18]. Epidemiological
evidence of the association between obesity and HCC is also
rapidly increasing including patients with HCV infection. In a
community-based cohort study, Chen et al. reported that obesity
was an independent risk factor for HCC development in anti-
HCV-seropositive subjects [9]. Therefore, we hypothesized that
serum adiponectin level may be associated with the prevalence of
HCC in patients with HCV infection. However, in this case-
control study, serum total and HMW adiponectin levels were not
significantly and inversely associated with the prevalence of HCC.
Similarly, Nkontchou et al. also demonstrated that serum level of
adiponectin is not predictive of HCC development in patients with
compensated HCV cirrhosis [29]. In patients with HCV infection,
it is well known that metabolic abnormalities such as obesity and
diabetes are closely associated with hepatic steatosis [4] and severe
fibrosis [5]; as a result, obesity affect as a partial factor of HCC
development. On the other hand, several recent reports have
shown that hypoadiponectinemia was associated with hepatic
steatosis only in limited genotype [30] and association between
hypoadiponectinemia and fibrosis progression was not found in
patients with HCV infection [31]. In addition, we assessed the
association between BMI and serum adiponectin levels in cases
and controls. Our results showed that these adiponectin levels
were not inversely associated with BMI, suggesting that adipo-
nectin is not a cofactor in the development of HCC associated with
obesity in patients with HCV infection.
Recently, several studies have been reported that serum
adiponectin level was associated with progression of liver fibrosis
in patients with chronic liver disease [19,20,21]. We also evaluated
the association between serum total and HMW adiponectin levels
and progression of liver fibrosis. APRI is a useful noninvasive
marker for the prediction of liver fibrosis in chronic liver disease
with HCV infection [28] and we assessed the degree of liver
fibrosis by APRI in this study. As a result, serum total and HMW
adiponectin levels were positively and significantly associated with
APRI in both cases and controls. Tietge et al. reported that
circulating adiponectin level increased in patients with liver
Figure 2. Serum adiponectin levels and body mass index (BMI). A. Correlation between serum total adiponectin levels and BMI in controls
(r=20.142, P=0.166). B. Correlation between serum high molecular adiponectin (HMW) adiponectin levels and BMI in controls (r=20.144, P=0.160).
C. Correlation between serum total adiponectin levels and BMI in cases (r=20.129, P=0.208). D. Correlation between serum HMW adiponectin levels
and BMI in cases (r=20.131, P=0.201).
doi:10.1371/journal.pone.0026840.g002
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adiponectin levels and APRI in controls (r=0.482, P,0.001). B. Correlation between serum high molecular adiponectin (HMW) adiponectin levels and
APRI in controls (r=0.476, P,0.001). C. Correlation between serum total adiponectin levels and APRI in cases (r=0.491, P,0.001). D. Correlation
between serum HMW adiponectin levels and APRI in cases (r=0.485, P,0.001).
doi:10.1371/journal.pone.0026840.g003
Table 2. Association between clinical characteristics and histological grade in patients with hepatocellular carcinoma.
Well Moderate Poor P value
Number 30 39 28
Age (years) 67.566.9 67.368.2 67.169.9 0.942
Gender (Female/Male) 11/19 12/27 7/21 0.630
AST (U/L) 67.2623.8 59.5628.8 59.3625.9 0.409
ALT (U/L) 61.0635.5 60.0633.1 53.5632.1 0.647
Platelet count (610
9/L) 103.1646.5 116.9647.6 125.1654.0 0.228
APRI 1.861.1 1.360.9 1.360.9 0.213
Child-Pugh grade (A/B+C) 22/8 36/3 24/4 0.095
Diabetes mellitus (Absent/Present) 24/6 21/18 19/9 0.073
BMI (kg/m
2) 22.563.2 22.463.0 22.663.5 0.949
AFP (ng/ml) 51.3674.4 165.06448.4 560.161508.8 0.065
DCP (mAU/ml) 65.56139.5 464.26978.8 276.16586.4 0.070
Tumor size (mm) 21.064.9 26.8610.0{ 26.6611.8{ 0.027
Tumor number (single/2–3) 19/11 29/10 19/9 0.609
Total adiponectin (mg/ml) 22.0613.6 13.466.9{ 11.567.3{ ,0.001
HMW adiponectin (mg/ml) 14.969.5 8.664.7{ 6.965.0{ ,0.001
Continuous variables presented as mean 6 standard deviation.
Abbreviation: AST=aspartate aminotransferase; ALT=alanine aminotransferase;
APRI=aspartate aminotransferase-to-platelet ratio index; BMI=body mass index;
AFP=alpha-fetoprotein; DCP=des-gamma-carboxy prothrombin; HMW=high molecular weigh.
{P,0.05 for Bonferroni corrected post hoc comparison with well-differentiated hepatocellular carcinoma.
doi:10.1371/journal.pone.0026840.t002
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adiponectin extraction and altered hepatic hemodynamics [20].
Taken together serum total and HMW adiponectin levels may be
a predictors of liver fibrosis in patients with HCV infection.
Next, we examined the relationship between serum adiponectin
levels and HCC histological grades. Interestingly, low total and
HMW adiponectin levels were independent risk factors for worse
HCC histological grades. It is generally known that majority of
HCC arises as very well-differentiated cancers and proliferate in a
stepwise process of dedifferentiation. When small HCC of the
early-stage reach around 1.5–2.0 cm, moderately or poorly
differentiated cancer tissues develops within the well-differentiated
cancer tissue, and well-differentiated cancer tissue are replaced by
less differentiated cancer tissue in so-called advanced HCC [32].
In this study, the mean tumor size of well-differentiated HCC was
14.263.2 mm, which was significantly smaller than the mean size
of moderately and poorly differentiated HCC. This result
indicated that a dedifferentiation of HCC is associated with tumor
proliferation.
This is a cross-sectional study and causal relationship between
serum adiponectin level and dedifferentiation of HCC is unclear.
One would think that dedifferentiation of HCC may trigger a
mechanism which leads to decreased serum adiponectin level.
However, it seems that hypoadiponectinemia may trigger
dedifferentiation of HCC because of followings: Saxena et al.
showed that adiponectin increased the phosphorylation of AMP-
activated protein kinase (AMPK) and the TSC2 tumor suppressor,
and inhibited phosphorylation of the mammalian target of
rapamycin (mTOR) in vitro assay using Huh7 and HepG2
HCC cells [11]. Moreover, microarray analysis of tissue
adiponectin expression levels in human HCC patients revealed
that adiponectin expression was inversely correlated with tumor
size [11]. Miyazaki et al. showed that adiponectin stimulated c-Jun
NH2-terminal kinase (JNK) activation and suppressed signal
transducer and activator of transcription 3 (STAT3) activation
in HepG2 HCC cells [33]. Thus, these studies support that
adiponectin level may inhibit proliferation and differentiation of
HCC.
Table 3. Association between total and HMW adiponectin and histological grade in patients with hepatocellular carcinoma by
multiple logistic regression analysis.
Model 1 Model 2
OR (95%CI) P value OR (95%CI) P value
Total adiponectin (mg/ml)
24, Reference Reference
12–24 6.67 (1.83–24.3) 0.004 9.33 (2.27–38.43) 0.002
,12 9.87 (2.76–35.2) ,0.001 11.76 (2.97–46.66) ,0.001
HMW adiponectin (mg/ml)
14, Reference Reference
7–14 4.38 (1.40–13.64) 0.011 5.67 (1.66–19.33) 0.006
,7 9.92 (2.91–33.85) ,0.001 10.24 (2.80–37.40) ,0.001
Abbreviation: OR=odds ratio; 95% CI=confidence interval; HMW=high molecular weigh.
Model 1: adiponectin only.
Model 2: adiponectin and covariates in Table 2.
doi:10.1371/journal.pone.0026840.t003
Figure 4. Comparison of adiponectin levels according to histological grades in 97 cases. A. The serum total adiponectin levels in patients
with moderately (P=0.001) and poorly (P,0.001) differentiated hepatocellular carcinoma (HCC) were significantly lower compared to those in
patients with well-differentiated HCC. B. The serum high molecular weight (HMW) adiponectin levels in patients with moderately (P,0.001) and
poorly (P,0.001) differentiated HCC were significantly lower compared to those in patients with well-differentiated HCC.
doi:10.1371/journal.pone.0026840.g004
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dedifferentiation, and metastasis of HCC. In small sized and well-
differentiated HCCs, artery-like vessels are not well developed
[34]. On the other hand, in moderately or poorly differentiated
HCCs with 2 cm or larger, artery-like vessels are well developed
[35], and these tumors display high proliferation and metastasis so-
called advanced stage. Vascular endothelial growth factor (VEGF)
is an endothelial cell-specific mitogen, and is the most important
factor in tumor angiogenesis [36]. Yamaguchi et al. showed that
VEGF expression in well-differentiated HCC was higher than
expression in moderately and poorly differentiated HCC [37].
Well-differentiated HCCs that are 1.0–1.5 cm would be in the
transitioning from the portal blood supply to an arterial blood
supply, which would result in increased VEGF expression because
of relative hypoxia from low blood flow. Therefore, high VEGF
expression in small-sized and Well-differentiated HCCs suggests
that VEGF plays an important role during relatively early
angiogenesis stages in HCC. Previous studies have reported on
the the molecular mechanisms involved in the negative association
of adiponectin with tumor angiogenesis [38,39]. Man et al. showed
in an orthotopic liver tumor nude mouse model that adiponectin
suppresses tumor growth through inhibition of tumor angiogenesis
[39]. The molecular mechanism involves adiponectin downregu-
lation of VEGF expression through inhibition of tumor-associated
macrophages in tumor tissue. Moreover, the nude mice admin-
istrated adiponectin had significantly lower circulating VEGF
levels than the control. This result suggests that adiponectin may
inhibit dedifferentiation in well-differentiated HCC by inhibition
of tumor angiogenesis-related VEGF.
Adiponectin exists mainly in three forms [12]. HMW
adiponectin is thought to have higher biological activity than the
other forms of adiponectin, especially in the liver [12,13]. Several
studies have reported that HMW adiponectin levels or the ratio of
HMW to total adiponectin is inversely and more strongly
associated with metabolic risk factors than total adiponectin levels
[40,41]. However, it remains unknown whether HMW adiponec-
tin has more strongly potential actions on cancer pathophysiology
than total adiponectin. In this study, we demonstrated that total
and HMW adiponectin were independent risk factors for HCC
histological grade. However, odds ratio of these factors were
similar and serum total adiponectin levels were significantly
associated with serum HMW adiponectin levels in this study (data
not shown). Thus, one would think that impact of HMW
adiponectin may be equal to total adiponectin for predicting
HCC histological grade and testing for either total or HMW
adiponectin levels may be as effective as testing both levels.
In conclusion, our data suggested that serum total and HMW
adiponectin levels were predictors of liver fibrosis, but not
prevalence of HCC in patients with chronic HCV infection.
Moreover, we showed that low total and HMW adiponectin levels
were independent risk factors for worse histological grades of
HCC. Further study will be focused on the causal relationship
between hypoadiponectinemia and dedifferentiation of HCC.
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